Volume 18, Issue 4 p. 568-574
SHORT REPORT

Patients' perceptions on shared decision making during prescription of subcutaneous biological drug treatments for inflammatory arthritis: The RHEU-LIFE survey

Javier de Toro

Javier de Toro

Department of Rheumatology, Hospital Universitario A Coruña, A Coruña, Spain

Search for more papers by this author
Carlos M. González

Carlos M. González

Department of Rheumatology, Hospital Universitario Gregorio Marañón, Madrid, Spain

Search for more papers by this author
Luis Cea-Calvo

Luis Cea-Calvo

Medical Affairs Department, MSD, Madrid, Spain

Search for more papers by this author
María J. Arteaga

María J. Arteaga

Medical Affairs Department, MSD, Madrid, Spain

Search for more papers by this author
Sabela Fernández

Sabela Fernández

Medical Affairs Department, MSD, Madrid, Spain

Search for more papers by this author
Loreto Carmona

Loreto Carmona

Instituto de Salud Musculoesquelética (InMusc), Madrid, Spain

Search for more papers by this author
Teresa Otón

Corresponding Author

Teresa Otón

Instituto de Salud Musculoesquelética (InMusc), Madrid, Spain

Correspondence

Teresa Otón, Instituto de Salud Musculoesquelética (InMusc), Calle Conde de la Cimera, 6, 28040 Madrid, Spain.

Email: teresa.oton@inmusc.eu

Search for more papers by this author
First published: 24 August 2020
Citations: 3

Abstract

Objectives

The aim of this study was to explore the preferences of patients with rheumatic diseases and their perceived experience regarding participation in shared decision making (SDM) when they were prescribed a subcutaneous (SC) biological drug.

Methods

A printed survey was handed to 1,000 patients with inflammatory rheumatic diseases treated with SC biological drug. The survey included closed questions about preferences regarding decision making and about patients' experience when they were prescribed an SC biological drug. Descriptive statistics were performed with stratification by patient profiles, using chi-square for comparisons between groups.

Results

A total of 592 surveys were received (response rate 59.2%, mean age 51.7 years, 57.6% women). Some 28.2% of patients reported preferring to take part in treatment selection, a percentage that was higher in younger patients, in those with higher academic degree and in those who search information in sources different to that of health care professionals. Over half of patients (56.3%) perceived that the rheumatologist considered their opinion when prescribing an SC biological drug, a percentage higher in younger people. Only in 40.8% of cases did the patients' preference match their perception of their participation in the process. No differences were observed by sex, disease or number of biologics.

Conclusions

Patients with inflammatory rheumatic diseases want information about their treatments but mostly leave the prescription decision to the rheumatologist. Younger people, or those with higher academic degree, more often want to participate in the SDM. There are discrepancies between patient preferences and perceptions of this process.

CONFLICT OF INTEREST

Luis Cea-Calvo, María J. Arteaga and Sabela Fernández are full-time employees of MSD Spain. The rest of the authors received fees as consultants for the present study. Carlos M. González has received speaker fees from MSD. The rest of the authors declare that they have no conflicts of interest.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.